Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Radiology
Published in: Japanese Journal of Radiology 9/2016

01-09-2016 | Original Article

Clinical utility of radiofrequency ablation following transarterial injection of miriplatin-iodized oil suspension in small hepatocellular carcinoma

Authors: Ken Nakajima, Takashi Yamanaka, Atsuhiro Nakatsuka, Takaki Haruyuki, Masashi Fujimori, Yuichi Sugino, Naritaka Matsushita, Hajime Sakuma, Shuji Isaji, Yoshiyuki Takei, Koichiro Yamakado

Published in: Japanese Journal of Radiology | Issue 9/2016

Login to get access

Abstract

Purpose

To retrospectively evaluate the clinical utility of radiofrequency ablation (RFA) following transarterial injection of miriplatin-iodized oil suspension (MPT–RFA) for hepatocellular carcinoma treatment.

Materials and methods

We evaluated clinical outcomes of MPT–RFA for three or fewer hepatocellular carcinomas. Twenty-one patients with 30 tumors (maximum diameter: mean 1.4 ± 0.4 cm, range 0.7–2.2 cm) received MPT–RFA.

Results

Nineteen patients (90.5 %, 19/21) achieved complete ablation at the first RFA session. Two patients (9.5 %, 2/21) required a second RFA session but achieved complete ablation. Primary and secondary technical success rates were 90.5 and 100 %. There were no deaths related to the procedures performed. Grade 3 or 4 increases in the serum aspartate aminotransferase, alanine aminotransferase, and bilirubin levels were found in six patients (38.1 %, 8/21). There were no liver infarctions. During the median follow-up period of 24.1 months (mean ± SD 24.7 ± 6.9 months, range 13.8–38.9 months), the local tumor progression rate and overall survival rate at 2 years was 5.0 % (95 % confidence interval 0.3–20.6 %) and 86.7 % (95 % confidence interval 56.3–96.5 %), respectively. The mean hospital stay was 8.4 ± 3.1 days (range 5–18 days).

Conclusion

MPT–RFA is a safe therapeutic option that initially provides therapeutic results.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6.CrossRefPubMed
2.
Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011;7:463–75.CrossRefPubMed
3.
Shiina S, Tateishi R, Arao T, Uchino K, Enooku K, Nagasawa H, asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107(4):569–77.
4.
Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252(3):905–13.CrossRefPubMed
5.
Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, Kim PN. Hepatocellular carcinomas 2–3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012;81(3):e189–93.
6.
Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60.CrossRefPubMed
7.
Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. Perivascular versus nonperivascular small HCC treated with percutaneous RF ablation: retrospective comparison of long-term therapeutic outcomes. Radiology. 2014;270(3):888–99.CrossRefPubMed
8.
Morimoto M, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, et al. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Interv Radiol. 2010;21:1716–24.CrossRefPubMed
9.
Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008;247:260–6.CrossRefPubMed
10.
Yamanaka T, Takaki H, Nakatsuka A, Uchida K, Junji U, Fujimori M, et al. Radiofrequency ablation after arterial injection of miriplatin-iodized oil suspension into swine liver: ablative zone size and tissue platinum concentration. Cardiovasc Intervent Radiol. 2014;37:1047–52.CrossRefPubMed
11.
Sugimori K, Nozawa A, Morimoto M, Shirato K, Kokawa A, Saito T, Tanaka K, et al. Extension of radiofrequency ablation of the liver by transcatheter arterial embolization with iodized oil and gelatin sponge: results in a pig model. J Vasc Interv Radiol. 2005;16(6):849–56.CrossRefPubMed
12.
Okusaka T, Kasugai H, Ishii H, Kudo M, Sata M, Tanaka K, et al. A randomized phase II trial of intra–arterial chemotherapy using SM–11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs. 2012;30:2015–25.CrossRefPubMed
13.
Takaki H, Yamakado K, Nakatsuka A, Yamada T, Uraki J, Kashima M, et al. Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images. Int J Clin Oncol. 2013;18:46–53.CrossRefPubMed
14.
Yamakado K, Nakatsuka A, Ohmori S, Shiraki K, Nakano T, Ikoma J, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002;13:1225–32.CrossRefPubMed
15.
Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentral
16.
Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol. 2007;188:480–8.CrossRefPubMed
17.
18.
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, International Working Group on Image-Guided Tumor Ablation, Interventional Oncology Sans Frontières Expert Panel, Technology Assessment Committee of the Society of Interventional Radiology, Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Interv Radiol. 2014;25(1691–705):e4.PubMed
19.
Yasui K, Takashima H, Miyagawa M, Miyazawa K, Ochiai T, Mukaisho K, et al. Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. Hepatol Res. 2013;43:1093–9.PubMed
20.
Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology. 2007;72(Suppl1):98–103.CrossRefPubMed
21.
McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol. 1990;25:267–70.CrossRefPubMed
22.
Rossi S, Fornari F, Pathies C, Buscarini L. Thermal lesions induced by 480 kHz localized current field in guinea pig and pig liver. Tumori. 1990;76:54–7.
23.
Takaki H, Yamakado K, Sakurai H, Nakatsuka A, Shiraki K, Isaji S, et al. Radiofrequency ablation combined with chemoembolization: treatment of recurrent hepatocellular carcinomas after hepatectomy. AJR Am J Roentgenol. 2011;197:488–94.CrossRefPubMed
24.
Yamanaka T, Yamakado K, Takaki H, Nakatsuka A, Shiraki K, Hasegawa H, et al. Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol. 2012;30:553–9.CrossRefPubMed
25.
Hasegawa T, Takaki H, Yamanaka T, Fujimori M, Nakatsuka A, Uraki J, et al. Experimental assessment of temperature influence on miriplatin and cisplatin iodized-oil suspension viscosity. Jpn J Radiol. 2013;31:424–7.CrossRefPubMed
26.
Yang W, Ahmed M, Elian M, Hady el–SA, Levchenko TS, Sawant RR, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010;257:685–96.CrossRefPubMedPubMedCentral
27.
Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology. 2005;235:469–77.CrossRefPubMed
28.
Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119–26.
Metadata
Title
Clinical utility of radiofrequency ablation following transarterial injection of miriplatin-iodized oil suspension in small hepatocellular carcinoma
Authors
Ken Nakajima
Takashi Yamanaka
Atsuhiro Nakatsuka
Takaki Haruyuki
Masashi Fujimori
Yuichi Sugino
Naritaka Matsushita
Hajime Sakuma
Shuji Isaji
Yoshiyuki Takei
Koichiro Yamakado
Publication date
01-09-2016
Publisher
Springer Japan
Published in
Japanese Journal of Radiology / Issue 9/2016
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-016-0567-x

Other articles of this Issue 9/2016

Japanese Journal of Radiology 9/2016 Go to the issue

Special Report

Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts

Original Article

Rebound adenoid hyperplasia after chemotherapy in pediatric patients with head and neck lymphoma: MR imaging findings

Original Article

Long-term results after 12-year follow-up of patients treated with whole-breast and boost irradiation after breast-conserving surgery

Original Article

Single-energy metal artifact reduction for helical computed tomography of the pelvis in patients with metal hip prostheses

Original Article

Can an enhanced thin-slice computed tomography delineate the right adrenal vein and improve the success rate?

Original Article

Diffusion weighted imaging in differentiating malignant and benign neuroblastic tumors